StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

Investment analysts at StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report issued on Saturday. The brokerage set a “buy” rating on the biotechnology company’s stock.

ADAP has been the topic of a number of other reports. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday, March 21st. Guggenheim cut their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Finally, Scotiabank decreased their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $0.21 on Friday. Adaptimmune Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.55. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The firm has a market cap of $52.71 million, a price-to-earnings ratio of -0.94 and a beta of 2.52. The stock has a 50 day moving average of $0.51 and a 200-day moving average of $0.66.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The business had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. As a group, analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several large investors have recently bought and sold shares of ADAP. Invesco Ltd. boosted its stake in Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after buying an additional 28,526 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares in the last quarter. Two Sigma Investments LP grew its position in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 94,623 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.